Madrigal Pharmaceuticals gains amid renewed takeover speculation

12.42BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US5588681057
CUSIP
87162T206
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
23.59
Dividend Share
-
Dividend Yield
-
Earnings Share
-13.73
Wall Street Target Price
680.00
EPS Estimate Current Year
-6.52
EPS Estimate Next Year
12.38
EPS Estimate Current Quarter
-4.144
EPS Estimate Next Quarter
-1.408
Most Recent Quarter
-
Revenue TTM
1,132,489,984
Gross Profit TTM
1,054,008,000
EBITDA
-311,996,000
Profit Margin
-27.32%
Return On Assets TTM
-17.62%
Return On Equity TTM
-49.35%
Revenue Per Share TTM
49.953
Qtly Revenue Growth YOY
126.80%
Diluted Eps TTM
-13.73
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
666
Price Sales TTM
11.1336
Price Book MRQ
22.826
Enterprise Value Revenue
10
Enterprise Value EBITDA
-8
760.00
3.03%22.75
2.52%865.00
0.00%88.94
0.00%124.85
-12.62%259.59
-12.18%853.82
-2.26%187.48
-2.14%476.99
-0.98%204.11
-0.83%